GlassScriptPhysician profile
Sohini Ghosh
NPI 1942592555
$111,743.55
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $15K · 2021: $23K · 2022: $27K · 2023: $12K · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $11K · Education: $8,150 · Food and Beverage: $5,085 · Travel and Lodging: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,700.00 |
| Consulting Fee | $10,665.00 |
| Education | $8,150.00 |
| Food and Beverage | $5,084.65 |
| Travel and Lodging | $1,999.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $49,249.93 | 2019-2025 | Da Vinci Sp |
| Astrazeneca Pharmaceuticals LP | $47,540.79 | 2019-2025 | Tagrisso, Imfinzi, Tezspire |
| Pulmonx Corporation | $12,318.25 | 2021-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Pinnacle Biologics, INC | $1,371.46 | 2022-2023 | Photofrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.88 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $290.18 | 2021-2023 | Dupixent |
| Glaxosmithkline, LLC. | $246.50 | 2021-2024 | Nucala |
| Galvanize Therapeutics, INC | $136.07 | 2023 | Aliya System |
| Ethicon INC. | $122.17 | 2023 | Monarch Platform |
| Boston Scientific Corporation | $65.05 | 2022 | |
| Covidien LP | $23.81 | 2019 | |
| Genzyme Corporation | $18.54 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohini Ghosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.